Clinical Report: Investigating the Function of PPFIA1 in Oncology

Overview

This study investigates the role of PPFIA1 in various cancers, particularly pancreatic cancer, highlighting its differential expression and prognostic implications. PPFIA1 overexpression correlates with adverse outcomes.

Background

Pancreatic cancer is characterized by poor prognosis and high mortality, with a projected rise in incidence. Identifying novel biomarkers like PPFIA1 could enhance early diagnosis and treatment strategies.

Data Highlights

Key Findings

• PPFIA1 is overexpressed in pancreatic adenocarcinoma compared to non-tumor tissues.
• High levels of PPFIA1 correlate with poor prognosis across multiple endpoints in pancreatic cancer.
• Genomic analyses show amplifications in head/neck cancers and mutations in endometrial carcinoma.
• GSEA analysis indicates activation of mitotic spindle assembly and EMT pathways in pancreatic cancer.
• ShRNA-mediated knockdown of PPFIA1 inhibits proliferation, migration, and invasion of pancreatic cancer cells.
• Elevated PPFIA1 levels are associated with improved responses to immunotherapy in pan-cancer cohorts.

Clinical Implications

The findings indicate that PPFIA1 may have prognostic significance in pancreatic cancer.

Conclusion

PPFIA1 is identified as a significant pan-cancer biomarker with potential implications for prognosis in pancreatic cancer.

Related Resources & Content

1. Gut, 2021 -- Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics
2. The ASCO Post, 2014 -- Research Insights From the AACR Special Conference on Pancreatic Cancer
3. the analytical scientist, 2026 -- Mass Spec Roundup: Proteoforms, PFAS, and Volatilomics…
4. The ASCO Post, 2018 -- NIH Completes In-Depth Genomic Analysis of 33 Cancer Types
5. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer - PMC, 2025
6. NCCN Guidelines® Insights, 2026 -- Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate
7. Liprin-α1 is a regulator of vimentin intermediate filament network in the cancer cell adhesion machinery - PMC, 2016
8. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer - PMC
9. NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026 - PubMed
10. Liprin-α1 is a regulator of vimentin intermediate filament network in the cancer cell adhesion machinery - PMC